• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of amjpatholAmerican Journal of Pathology For AuthorsAmerican Journal of Pathology SubscribeAmerican Journal of Pathology SearchAmerican Journal of Pathology Current IssueAmerican Journal of Pathology About the JournalAmerican Journal of Pathology
Am J Pathol. Nov 1999; 155(5): 1427–1432.
PMCID: PMC1866967

Focal Loss of CD44 Variant Protein Expression is Related to Recurrence in Superficial Bladder Carcinoma

Abstract

The majority of papillary transitional cell carcinomas of the bladder are localized tumors at initial diagnosis; identification of those developing recurrence and an aggressive behavior is important. CD44 variant proteins have been implicated in tumor progression and metastasis, and a correlation with adverse prognosis has been demonstrated in a variety of human tumors. Here, the usefulness of conventional CD44 protein immunohistochemistry as a prognostic parameter for recurrence of superficial transitional cell carcinomas was assessed in paraffin sections of 241 tumors with long-term follow-up. A highly significant association was found between focal loss of CD44v3 and -v6 immunostaining and short recurrence-free interval in noninvasive (pTa) transitional cell carcinomas (P = 0.005), but not in minimally invasive (pT1) carcinomas (P = 0.78). Our results indicate the value of conventional CD44 immunohistochemistry as an additional tool for identifying patients at high risk for recurrence of pTa transitional cell carcinomas. They also point to biological differences between noninvasive and minimally invasive transitional cell carcinomas of the bladder.

Transitional cell carcinoma (TCC) of the urinary bladder presents a spectrum of tumors ranging from indolent, noninvasive to diffuse, invasive, highly aggressive bladder cancer. The majority of TCCs present as either localized noninvasive (pTa) or minimally invasive (pT1) tumors at time of initial diagnosis. At that time, the identification of TCCs with a high probability of developing recurrence and an aggressive course is important for the management of the patients. The histological grade, tumor stage, and tumor number are considered important prognostic factors in bladder cancer. 1-3 However, the grading and staging of urinary bladder cancer suffer from low interobserver reproducibility. 4,5 There is a need for better prognosticators that are not only independent of grade and stage but are also more reproducible than the currently used histological parameters.

CD44 glycoproteins are promising candidates, because the CD44 variant glycoprotein containing sequences encoded by exon 6 has been shown to confer metastatic potential on rat pancreatic carcinoma cells 6,7 and to be implicated in progression and metastasis formation in various human malignancies. 8 The transitional epithelium of urinary bladder and cell lines derived from it, as well as cell lines from TCCs, have been shown to express various CD44 isoforms including CD44v3, -v4, -v5, and -v9. 9,10 In addition, retention of certain intronic sequences has been reported to occur frequently in TCC but hardly ever in normal transitional epithelium. 11 Recent studies have shown that CD44v6 expression is reduced in poorly differentiated, invasive TCCs, as compared to well or moderately differentiated noninvasive tumors. 12-14 Furthermore, a correlation between CD44 expression and prognosis has been reported. 13 In long-term follow-up, strong expression of CD44v6 was related to high survival probability and independently related to favorable outcome in muscle invasive tumors, whereas standard CD44 was an independent prognostic factor in superficial tumors. Other investigators, however, failed to establish a prognostic value for CD44v6 for tumor recurrence and patient survival. 15

Based on our previously obtained data on a small collection of superficial TCCs, 16 we have evaluated the value of CD44 immunohistochemistry in predicting recurrence in 241 superficial (pTa and pT1) TCCs from patients for whom long-term follow-up data were available. Here we show that focal loss of immunostaining, observed with monoclonal antibodies against CD44v3 and -v6 protein, is a significant prognostic factor that helps to identify patients at high risk for recurrence of noninvasive (pTa) TCCs.

Materials and Methods

Patients and Tissue Samples

Formalin-fixed, paraffin-embedded tissue samples of primary TCCs of the urinary bladder were available from the archives of the Institute of Pathology at the University of Basel, the Cantonal Hospital St. Gallen, and the Triemli Hospital in Zurich, Switzerland. The series consisted of 241 superficial bladder carcinomas (pTa and pT1). Tumor stage and grade were defined according to UICC and WHO classifications. 17,18 One pathologist (G. S.) reviewed all slides of all tumors. Stage pT1 was defined by the presence of both unequivocal tumor invasion of the suburothelial stroma and tumor-free fragments of the muscular bladder wall. Biopsies containing carcinoma with stroma invasion, but lacking fragments of the muscular bladder wall, were excluded, as were true papillomas (grade 0). Of the 241 cases of superficial TCCs, 167 (69.3%) were pTa and 74 (30.7%) were pT1; 65 (27.4%) were G1, 127 (52.7%) were G2, and 49 (20.3%) were G3.

Clinical histories of patients (194 males, 47 females) with superficial bladder cancer were retrospectively evaluated by reviewing the patients’ charts and contacting the attending physicians. The average age of these patients was 65.6 years (range, 20–92 years). Regular follow-up cystoscopies had been performed at least at 3, 9, and 15 months, then annually until the endpoint of this study (recurrence, progression, or last control). Information on the number of tumors present in the bladder was obtained for 172 patients (75 multicentric, 97 unicentric). The medium follow-up period was 54 months (range, 6–167 months). Intravesical treatment had been performed in 60 patients (mitomycin in 29, BCG in 26, epirubicin in 2, fenorubicin in 2, adriblastin in 1, tigason in 1, and tumosteron in 1 patient). Recurrences were defined as cystoscopically visible tumors. Tumor progression was defined as the presence of muscle invasion (stage pT2 or higher) in a subsequent biopsy. An increase in stage from pTa to pT1 was not defined as progression because not all subsequent biopsies of our patients were available for review. Such a review is mandatory for studies investigating pTa-to-pT1 progression because of the interobserver variability among different pathologists, ranging from 25 to 40%, for the distinction of pTa and pT1. 4,5

Immunohistochemistry

CD44 protein expression was analyzed immunohistochemically, employing protein A-purified mouse monoclonal IgG reactive with CD44 protein isoforms containing human variant exons 3 (clone 3G5) and human variant exons 6 (clone 2F10) purchased from R&D Systems (Abingdon, UK). Immunostaining for CD44 was performed on paraffin sections, applying microwave antigen retrieval as previously described. 19 After quenching of endogenous peroxidase activity (0.6% H2O2 in absolute methanol, 15 minutes) and section conditioning 20 with 1.5% normal horse serum and 4% fat-free milk in isotonic Tris-HCl buffer, pH 6.5, for 20 minutes, sections were incubated with primary antibodies (1 μg/ml) for 60 minutes. Following buffer rinses, sections were processed by a streptavidin-biotin-peroxidase technique according to the manufacturer’s recommendations (Jackson ImmunoResearch Laboratories, West Grove, PA). Peroxidase activity was revealed according to Adams. 21

Specificity controls included the omission of primary and/or secondary antibodies as negative controls and the use of normal skin as positive controls.

Evaluation of Immunostaining and Statistical Analysis

During the whole immunohistochemical evaluation, the observers were blinded for disease outcome. A first evaluation scheme assessed the CD44-positive tumor cut surface area regardless of the staining intensity. Tumors were grouped into those with ≥50% and those with <50% positive tumor cut surface. Furthermore, focal loss of immunostaining for both CCD44v3 and -v6 was evaluated in serial sections. Focal loss of immunostaining was defined as the appearance of variably sized regions of the urothelium lacking immunoreactivity with the monoclonal antibodies throughout its entire thickness. The second scheme evaluated the dominant pattern of immunostaining. Homogenous staining was defined as extending evenly through the entire thickness of the neoplastic urothelium, whereas restricted immunostaining was defined as extending through less than 3/4 of the thickness.

Relationships between variables obtained in form of frequency tables were statistically analyzed using the χ 2 test. 22 Survival curves regarding tumor recurrence were obtained according to Kaplan-Meier and the significance of their differences was assessed by the log-rank test. Hazard ratios indicating the relative risk of recurrence of one group compared with the other were calculated. A Cox proportional hazard model was used to determine the parameters, with greatest influence on the risk of recurrence and progression.

Results

CD44v3 and -v6 Expression in Normal Transitional Epithelium and Superficial TCC

Transitional epithelium adjacent to tumors exhibited immunolabeling in the basal cell layer, decreasing in intensity toward the surface, with the most superficial layers of the urothelium including the umbrella cells being unlabeled, as reported by others. 10,12,13 In the 241 TCCs investigated, two prevailing staining patterns were observed: restricted staining extending through less than 3/4 of the urothelium thickness and homogenous staining extending evenly through the entire thickness of the neoplastic urothelium (Figure 1) [triangle] . Tumors exhibiting either of these labeling patterns could present variably sized regions with loss of immunostaining (Figure 1) [triangle] . Such a focal loss of immunostaining was strongly associated with advanced tumor stage and high histological grade. A focal loss of immunostaining was found in 89 of 167 pTa (53.3%), 66 of 74 pT1 (89.2%; P < 0.0001 for pTa vs. pT1), 28 of 65 G1 (43.1%), 79 of 127 G2 (62.2%), and 48 of 49 G3 tumors (98.0%, P < 0.0001, three-group contingency table analysis for grade).

Figure 1.
Immunohistochemical demonstration of CD44v3 and -v6 protein in noninvasive (pTa) transitional cell carcinoma; serial paraffin sections; heavy metal-intensified diaminobenzidine reaction. Tumors exhibit either a homogeneous immunostaining extending through ...

Relationship between CD44 Immunostaining Pattern and Tumor Recurrence and Progression

In our collective, 129 of 241 (53.5%) patients suffered from recurrent disease. To determine the predictive value of CD44 immunohistochemistry for recurrence of superficial TCCs, the initial biopsies of all pTa and pT1 tumor patients, with and without recurrent disease, were analyzed. Among the parameters analyzed, a significant difference was observed only in association with focal loss of immunostaining for both CD44v3 and -v6 protein. The group of pTa/pT1 TCCs exhibiting unlabeled areas for both CD44v3 and -v6, irrespective of their size (≥50% or <50% positive tumor cut surface), had a significantly shorter recurrence-free interval (P = 0.0132, Figure 2a [triangle] ) and was at significantly higher risk of developing tumor recurrence (hazard ratio 1.26, confidence limits 1.05–1.53). None of the other analyzed staining patterns distinguished tumors with recurrence from those without (data not shown). In addition, several subgroups of the patient collective were analyzed regarding the association between focal loss of immunostaining and recurrence. Although patients with noninvasive pTa tumors showed a significant difference in recurrence-free survival (P = 0.005, hazard ratio 1.34, confidence limits 1.09–1.67, Figure 2b [triangle] ), the group of minimally invasive pT1 tumors did not (P = 0.864). The association with recurrence was preserved in the subgroup of patients with pTa tumors who had not received chemotherapy (P = 0.031). The group of pTa TCCs with chemotherapy was too small for statistical analysis (n = 33). Multicentricity (P = 0.008), but not grade (P = 0.750, Figure 2c [triangle] ) or stage (P = 0.689), was linked to an increased risk of tumor recurrences in univariate analysis. A multivariate analysis of our collective, including grade (P = 0.58), stage (P = 0.50), multicentricity (P = 0.013), and focal loss of immunostaining (P = 0.063), revealed that only multicentricity (P = 0.013) was an independent predictor of recurrences, whereas focal loss of immunostaining (P = 0.063) did not reach the level of significance.

Figure 2.
Kaplan-Meier curves of recurrence-free interval. Focal loss of immunostaining for both CD44v3 and -v6 in the group of pTa and pT1 together (a), as well as in the pTa group alone (b), is correlated with significantly shorter recurrence-free interval of ...

Only eleven of our patients (eight pT1, three pTa) suffered from disease progression, thus limiting the potential of this patient set to identify molecular changes associated with progression. The progression rate for pT1 carcinomas was low in this patient set, probably because of our stringent definition of stage pT1. Tumor stage (P = 0.0003, Figure 2d [triangle] ) and, to a lesser extent, multicentricity (P = 0.050) and focal loss of immunostaining (P = 0.055), were related to tumor progression in univariate analysis, but not the histological grade (P = 0.301). In multivariate analysis, only stage (P < 0.0001) and multicentricity (P = 0.014) were linked to subsequent tumor progression, not grade (P = 0.645) or focal loss of immunostaining (P = 0.141).

Discussion

Recurrence of TCC cannot be predicted unequivocally at time of initial diagnosis using criteria such as histological grade, depth of invasion, and number of tumors. Hence, additional prognosticators for recurrence of TCC would be desirable. In the present study, we have investigated the relationship between the immunohistochemical expression of two CD44 protein variants and various clinicopathological features of superficial TCCs. Our data provide evidence for the value of CD44v3 and -v6 immunohistochemistry in identifying patients with superficial TCC at high risk for tumor recurrence.

We found that focal loss of CD44v3 and -v6 immunostaining in the biopsies proved to be of predictive value for recurrence in superficial TCCs. Although the loss of immunostaining varied in size, variation of this parameter was not of additional significance, because TCCs exhibiting ≥50% behaved similarly to those with <50% unstained tumor cut surface area. Focal loss of immunostaining occurred in the great majority of invasive and in half of noninvasive tumors. Although related to recurrence in the noninvasive group, CD44 was not related to progression in the two groups. Because focal CD44 loss occurred in most tumors, it is unlikely to be a causal event in progression. It will be interesting to determine how focal loss of CD44 immunostaining is related to other prognostic factors in superficial bladder cancer. It must be emphasized that our study was performed on routinely formaldhyde-fixed and paraffin-embedded tumor tissue using a standard antigen retrieval technique, 23 commercially available reagents, and a standard immunohistochemical procedure. Thus, detection of focal loss of immunostaining for CD44v3 and -v6 is easily practicable in surgical pathology laboratories. We observed differences between noninvasive (pTa) and minimally invasive (pT1) tumors. Patients with noninvasive TCCs displaying areas with loss of labeling for both CD44v3 and -v6 showed a significantly shorter recurrence-free survival time, whereas no such correlation could be established for minimally invasive (pT1) tumors. These findings are consistent with other marked genetic differences found between pTa and pT1 TCCs. 24,25 From the present results it can be concluded that loss of immunostaining for CD44v3 and -v6 protein is an event occurring early during progression of TCC and represents a useful prognostic factor for recurrence. It could be speculated that CD44v3- and -v6-negative tumor areas might consist of an expanding subpopulation of tumor cells with more aggressive growth properties.

In agreement with previously published data on CD44 expression, 12-14,26 an inverse correlation existed between the expression of CD44v3 and -v6 proteins and histological grade, as well as tumor stage. Similar observations were made for carcinomas derived from other stratified epithelia, such as squamous cell carcinomas of the skin, 19 and for breast carcinoma. 27 Thus, reduced expression of CD44 variant forms may have prognostic value in certain carcinoma types, whereas in others, including renal cell 28 and colorectal carcinomas, 29 overexpression seems to be positively correlated with tumor differentiation and to have prognostic value.

From the present findings arises the question whether the altered CD44 protein expression and tumor recurrence in TCCs are causally related. We recognize that immunohistochemistry neither permits direct studies of the complex splice patterns present in carcinomas, including TCC, 9 nor reveals the composition of these different variants and their functions. One might speculate that the absence of larger CD44 variant molecules at the cell surface may facilitate cell detachment and favor interaction of shorter CD44 molecules with the extracellular matrix to permit migration and invasion, as shown for melanoma cell lines. 30,31 It is also possible that the changed CD44 expression represents solely an epiphenomenon of dedifferentiation, which occurs in parallel to processes that cause tumor recurrence and invasion in TCCs. Indeed, a simultaneously occurring decrease in the expression of CD44v6, E-cadherin, 12,15 and α6β4 integrin 32 could be demonstrated in invasive TCC.

In conclusion, our current findings provide further evidence of the involvement of CD44 splice variants in the tumorigenesis of TCC. In terms of diagnosis and practicability, they show that detection of focal loss of immunohistochemical staining for CD44v3- and -v6-containing isoforms may provide an additional parameter in identifying patients with TCC at risk for tumor recurrence and that this information can be obtained on formalin-fixed, paraffin-embedded tissues. This immunohistochemical evaluation may be especially useful because the extent of loss of staining does not seem to be important and the identification of one area with unequivocal loss of immunostaining may be sufficient to define an increased risk for recurrence in affected patients.

Acknowledgments

We thank Diana Pauli for correcting the manuscript and Norbert Wey for help in preparing the micrographs.

Footnotes

Address reprint requests to Jürgen Roth, M.D., Ph.D., Division of Cell and Molecular Pathology, Department of Pathology, University of Zürich, Schmelzbergstrasse 12, CH-8091 Zürich, Switzerland. E-mail: .hc.zsu.ytp@htor.negreuj

Supported by the Swiss National Science Foundation and the Canton of Zürich. V. T. was recipient of a special educational grant from the University Hospital Zürich.

References

1. Kaubisch S, Lum B, Reese J, Freiha F, Torti F: Stage T1 bladder cancer: grade is the primary determinant for risk of muscle invasion. J Urol 1991, 146:28-31 [PubMed]
2. Jordan A, Weingarten J, Murphy WM: Transitional cell neoplasms of the urinary bladder: can biologic potential be predicted from histologic grading? Cancer 1987, 60:2766-2774 [PubMed]
3. Prout GR, Bassil B, Griffin P: The treated histories of patients with Ta grade 1 transitional-cell carcinoma of the bladder. Arch Surg 1986, 121:1463-1468 [PubMed]
4. Sauter G, Mihatsch M: Pussycats and baby tigers: non-invasive (pTa) and minimally invasive (pT1) bladder carcinomas are not the same! J Pathol 1998, 185:339-341 [PubMed]
5. Abel P, Henderson D, Bennett M, Hall R, Williams G: Differing interpretations by pathologists of the pT category and grade of transitional cancer of the bladder. Br J Urol 1988, 62:339-342 [PubMed]
6. Arch R, Wirth K, Hofmann M, Ponta H, Matzku S, Herrlich P, Zoller M: Prevention of tumor metastasis formation by anti-variant CD44. J Exp Med 1993, 177:443-55 [PMC free article] [PubMed]
7. Günthert U, Hofmann M, Rudy W, Reber S, Zoller M, Haussmann I, Matzku S, Wenzel A, Ponta H, Herrlich P: A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 1991, 65:13-24 [PubMed]
8. Günthert U: CD 44 in malignant disorders. Curr Top Microbiol Immunol 1996, 213:271-285 [PubMed]
9. Matsumura Y, Hanbury D, Smith J, Tarin D: Non-invasive detection of malignancy by identification of unusual CD44 gene activity in exfoliated cancer cells. Br Med J 1994, 308:619-624 [PMC free article] [PubMed]
10. Southgate J, Trejdosiewicz L, Smith B, Selby P: Patterns of splice variant CD44 expression by normal human urothelium in situ and in vitro and by bladder-carcinoma cell lines. Int J Cancer 1995, 62:449-456 [PubMed]
11. Matsumura Y, Sugiyama M, Matsumura S, Hayle A, Robinson P, Smith J, Tarin D: Unusual retention of introns in CD44 gene transcripts in bladder cancer provides new diagnostic and clinical oncological opportunities. J Pathol 1995, 177:11-20 [PubMed]
12. Hong RL, Pu YS, Chu JS, Lee WJ, Chen YC, Wu CW: Correlation of expression of CD44 isoforms and E-cadherin with differentiation in human urothelial cell lines and transitional cell carcinoma. Cancer Lett 1995, 89:81-87 [PubMed]
13. Lipponen P, Aaltoma S, Kosma VM, AlaOpas M, Eskelinen M: Expression of CD44 standard and variant-v6 proteins in transitional cell bladder tumours and their relation to prognosis during a long-term follow-up. J Pathol 1998, 186:157-164 [PubMed]
14. Ross JS, Delrosario AD, Bui HX, Kallakury BVS, Okby NT, Figge J: Expression of the CD44 cell adhesion molecule in urinary bladder transitional cell carcinoma. Mod Pathol 1996, 9:854-860 [PubMed]
15. Hong R, Pu Y, Hsieh T, Chu J, WJ L: Expressions of E-cadherin and exon v6-containing isoforms of CD44 and their prognostic values in human transitional cell carcinoma. J Urol 1995, 153:2025-2028 [PubMed]
16. Seelentag W, Donada-Graf S, Hailemariam S, Futo E, Günthert U, Heitz P, Roth J: CD44 isoform expression in human transitional cell carcinoma of the urinary bladder: correlation with degree of differentiation and tumor stage rather than with clinical course. Verh Dt Ges Path 1996, 80:419
17. Mostofi F, Sobin L, Torloni H: Histologic typing of urinary bladder tumours. 1973. World Health Organization, Geneva
18. Spiessl B, Beahrs OH, Hermanek P, Hutter RVP, Scheibe O, Sobin LH, Wagner G: TNM Atlas: Illustrated Guide to the TNM/pTNM Classification of Malignant Tumours. 1992. Heidelberg, New York, Berlin
19. Seelentag W, Saremaslani P, Futo E, Günthert U, Pfalz M, Heitz PU, Roth J: Expression patterns of CD44 standard and splice variants in human skin tumors are correlated with the degree of tumor differentiation. Int J Cancer 1996, 69:218-224 [PubMed]
20. Roth J, Taatjes DJ, Warhol MJ: Prevention of non-specific interactions of gold-labeled reagents on tissue sections. Histochemistry 1989, 92:47-56 [PubMed]
21. Adams J: Heavy metal intensification of DAB-based HRP reaction product. J Histochem Cytochem 1981, 29:775. [PubMed]
22. Altman D: Practical Statistics for Medical Research. 1995. Chapman & Hall, London
23. Werner M, Wasielewski RV, Komminoth P: Antigen retrieval, signal amplification and intensification in immunohistochemistry. Histochem Cell Biol 1996, 105:253-260 [PubMed]
24. Simon R, Bürger H, Brinkschmidt C, Böcker W, Hertle L, Terpe H: Chromosomal aberrations associated with invasion in papillary superficial bladder cancer. J Pathol 1998, 185:345-351 [PubMed]
25. Richter J, Beffa L, Wagne U, Schraml P, Gasser T, Moch H, Mihatsch M, Sauter G: Patterns of chromosomal imbalances in advanced urinary bladder cancer detected by comparative genomic hybridization. Am J Pathol 1998, 153:1615-1621 [PMC free article] [PubMed]
26. Sugino T, Gorham H, Yoshida K, Bolodeoku J, Nargund V, Cranston D, Goodison S, Tarin D: Progressive loss of CD44 gene expression in invasive bladder cancer. Am J Pathol 1996, 149:873-882 [PMC free article] [PubMed]
27. Friedrichs K, Kügler K, Franke F, Terpe HJ, Arit J, Regidor PA, Günthert U: CD44 isoforms in prognosis of breast cancer. Lancet 1995, 345:1237. [PubMed]
28. Terpe H, Storkel S, Zimmer U, Anquez V, Fischer C, Pantel K, Gunthert U: Expression of CD44 isoforms in renal cell tumors: positive correlation to tumor differentiation. Am J Pathol 1996, 148:453-463 [PMC free article] [PubMed]
29. Wielenga VJM, VanderVoort R, Mulder JWR, Kruyt PM, Weidema WF, Oosting J, Seldenrijk CA, VanKrimpen C, Offerhaus GJA, Pals ST: CD44 splice variants as prognostic markers in colorectal cancer. Scand J Gastroenterol 1998, 33:82-87 [PubMed]
30. Thomas L, Etoh T, Stamenkovic I, Mihm M, Byers H: Migration of human melanoma cells on hyaluronate is related to CD44 expression. J Invest Dermatol 1993, 100:115-120 [PubMed]
31. Bartolazzi A, Peach R, Aruffo A, Stamenkovic I: Interaction between CD44 and hyaluronate is directly implicated in the regulation of tumor development. J Exp Med 1994, 180:53-66 [PMC free article] [PubMed]
32. Liebert M, Washington R, Wedemeyer G, Carey T, Grossman H: Loss of co-localization of α6β4 integrin and collagen VII in bladder cancer. Am J Pathol 1994, 144:787-795 [PMC free article] [PubMed]

Articles from The American Journal of Pathology are provided here courtesy of American Society for Investigative Pathology
PubReader format: click here to try

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

  • Cited in Books
    Cited in Books
    PubMed Central articles cited in books
  • MedGen
    MedGen
    Related information in MedGen
  • PubMed
    PubMed
    PubMed citations for these articles

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...